Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you take an oral contraceptive pill and are starting Mounjaro, there is one specific precaution you need to follow: add a non-oral method of contraception — such as condoms — for the first four weeks of treatment and for four weeks after every dose increase. This is the advice from NHS England and the MHRA, because tirzepatide slows gastric emptying and may reduce how well your body absorbs the pill during that window. Beyond that adjustment period, current evidence does not suggest your pill stops working. That said, this is a prescription-only medicine, and whether tirzepatide is right for you, and how contraception fits around it, is a conversation your prescriber needs to be part of.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people starting Mounjaro assume that because it affects the gut, it must interfere with the pill in a lasting or serious way, effectively cancelling out contraception. That isn't what the evidence shows. The concern is narrower: because tirzepatide slows how quickly food and medicines move through your stomach, the pill's absorption can be reduced during the early weeks of treatment and each time your dose steps up. Outside those windows, there is no current clinical evidence that the pill loses effectiveness.
It is an easy misconception to pick up, and it matters to correct it, not because the risk is trivial, but because the right response is a targeted, time-limited adjustment, not abandoning oral contraception altogether. If you have been worried you need to change your entire contraception method, you can let that go. The guidance is more manageable than the rumour.
There is a fuller explanation of how the pill specifically interacts with Mounjaro if you want to go deeper on the pharmacology, but the practical summary is straightforward.
NHS England's guidance on weight-management injections is explicit on this point. Women using an oral contraceptive pill should use an additional non-oral contraceptive method (a barrier method such as condoms) for the first four weeks of starting Mounjaro and for four weeks after every dose increase. That covers the period when gastric emptying is most affected by the change in medicine or dose.
This precaution is specific to tirzepatide. NHS inform Scotland notes that the same evidence of reduced pill effectiveness does not currently exist for semaglutide, which is relevant if you are comparing the two treatments and contraception is a factor in your thinking.
Beyond the oral pill, non-oral hormonal contraception (patches, implants, injections, hormonal coils) is not absorbed through the gut and so is not subject to the same concern. The guidance makes no equivalent recommendation for those methods.
The MHRA also advises using effective contraception throughout Mounjaro treatment. If you are considering pregnancy in the future, discuss timing with your prescriber; there is a recommended wash-out period before trying to conceive. Mounjaro is not recommended during pregnancy or while breastfeeding under any circumstances.
Contraception isn't the only area where Mounjaro's effect on absorption matters. NHS England also recommends considering transdermal HRT (patches or gels rather than oral tablets) while on tirzepatide, for the same gastric-emptying reason. If you take HRT orally, it is worth raising this with your GP or prescriber before or shortly after starting treatment.
Surgery is a separate but related consideration. If you are due any procedure requiring an anaesthetic, your surgical team and anaesthetist need to know you are taking Mounjaro. Delayed gastric emptying carries specific risks under general anaesthesia. The Mounjaro overview page covers these interactions in more detail, alongside the full licensed-use context for tirzepatide in the UK.
There are also occasional questions about alcohol on treatment. It doesn't interact with Mounjaro's absorption in the way oral medicines do, but nausea and other gastrointestinal effects can be amplified; there is specific guidance on drinking alcohol while taking Mounjaro if that is relevant to you.
Your GP, contraception clinic, or a prescriber at a regulated online pharmacy can all advise on how to handle this in practice. What matters is that whoever manages your contraception knows you are taking tirzepatide, and whoever prescribes your Mounjaro knows what contraception you use.
At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not an automated decision) on the same day you submit it. Contraception is part of the clinical picture they assess. If there is anything in your medical history or current medication that needs discussion, it gets discussed before any prescription is issued. That is not a formality; for situations like this one, it is the part that actually matters.
If you have questions before starting, the nume FAQs cover some common concerns, and you can reach the team directly via the contact page. If you are ready to begin the process, speak to our prescribers through a free consultation, the clinical review happens the same day.
For background on whether Mounjaro stops contraception working entirely, or for the specifics of tirzepatide alongside oral contraceptives more broadly, those pages set out what the evidence does and doesn't show in plain terms.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.